The virus that causes the acquired immunodeficiency syndrome (AIDS), human T lymphotropic virus/lymphadenopathy-associated virus (HTLV-III/LAV), was incubated at temperatures from 370 to 60'C and virus titer 
Introduction
Transmission of the acquired immunodeficiency syndrome (AIDS)' by plasma products is a major concern, particularly to the hemophilia community (1) . At the request of the National Hemophilia Foundation Medical and Scientific Advisory Council, we conducted thermal stability studies with the AIDS virus (human T lymphotropic virus type III/lymphadenopathy-associated virus, HTLV-III/LAV). Preliminary data presented to the Advisory Council at the Centers for Disease Control (CDC) in September 1984 formed the scientific basis for their subsequent recommendation that heat-treated lyophilized antihemophilic Factor VIII and Factor IX concentrates 1. Abbreviations used in this paper: AIDS, acquired immunodeficiency syndrome; CDC, Centers for Disease Control; HTLV-III/LAV, human T lymphotropic virus/lymphadenopathy-associated virus; ID-50, virus titer; IL-2, interleukin-2; PHA, phytohemagglutin; RT, reverse transcriptase.
The Journal of Clinical Investigation, Inc. Volume 76, August 1985, 875-877 be used in the treatment of hemophilia (2). We now report more extensive data that support this recommendation.
Methods
HTLV-III/LAV was propagated in normal phytohemagglutin (PHA)-stimulated lymphocytes which were cultured in RPMI media (Gibco Laboratories, Grand Island, NY) containing 10% vol/vol fetal calf serum (Gibco Laboratories) and 10% vol/vol interleukin-2 (IL-2; Cellular Products, Buffalo, NY) as previously described (3). Culture supernates was harvested when virus levels had peaked as determined by reverse transcriptase (RT) activity and immunoassay for virus antigen (3). Supernates were sequentially centrifuged at 300 g for 7 min and 1,500 g for 20 min and stored in 0.5-to l.0-ml aliquots in liquid nitrogen. Virus inocula used in these studies had infectivity titers of> lO.
The microculture assay for the titration of infectious HTLV-HII/ LAV has been described in detail (3) . Briefly, PHA-stimulated normal human lymphocytes are inoculated with serial 10-fold dilutions of virus inoculum and incubated for 18 h at 370C. The cells are then washed and plated in microculture (10-20 cultures/dilution; I X 101 cells/culture in 0.25 ml of media). Every 3 d, 100 ll of supernate is removed and replaced with fresh media. The supernates are then assayed for virus by an antigen capture assay (3). Infectious virus titer (ID-50) is defined as the reciprocal of the dilution at which 50% of the cultures are positive for virus (3, 4) . Previously established (3) features of the infectivity assay system relevant to the interpretation of the thermal inactivation experiments include the following: tht antigen capture assay is as sensitive as the RT assay for detecting supernate virus (3). The ID-50 assay, in turn, is several orders of magnitude more sensitive than either assay for detecting small amounts of virus (3) . In the ID-O50 assay, active virus replication is required to obtain a measurable titer. After incubation with virus, the infected cells are washed, and any antigen carryover from the inoculum is insufficient to register a positive virus capture assay result (3).
For thermal inactivation of virus in a liquid matrix, aliquots of the virus inoculum (HTLV-III/LAV in RPMI media containing 10% fetal calfserum and 10% IL-2) were incubated at the temperatures indicated.
Exposure times were staggered such that all incubations were terminated at the same time. Aliquots were placed in an ice bath and diluted in media, and ID-50 titrations were performed.
Virus inocula were shipped on dry ice to several manufacturers of factor concentrates. They mixed one part inoculum with nine parts liquid antihemophilic factor, Iyophilized the material, and heated it. Then, they returned the freeze-thawed virus inoculum, prelyophilization specimens, postlyophilization specimens, and post heat-treatment specimens to CDC on dry ice. Uninoculated antihemophilic factor preparations, which were processed in parallel, met the manufacturers' specifications for potency (factor activity) and residual moisture analysis. 
Results
Thermal inactivation of HTLV-III/LAV in a liquid matrix was performed on a virus inoculum with an ID-50 titer of >105 (Fig. 1 The thermal decay of virus in a matrix of 90% normal human serum at 560C was similar to that of virus in culture media (D,0 of 117 and 121 s, respectively). The thermal decays at 60'C of an HTLV-III/LAV inoculum in liquid Factor VIII (DIo = 22 s) and liquid Factor VIII stabilized with 50% sucrose and 2 M glycine (D1o = 30 s) were similar to that of virus in culture media (D10 = 24 s) (Fig. 2) . The thermal decay of virus lyophilized in Factor VIII was more prolonged (DIo = 32 min) (Fig. 2) . ID-50 data were also derived on virus inocula that were lyophilized with Factor VIII or Factor IX and heat-treated according to manufacturers' protocols (Table  I) (3) . However, the relationship between the lower limits of sensitivity for infectious virus in this assay and infectivity in man is unknown. The only information we have bearing on this is that one chimpanzee inoculated with a dose of 1120 ID-50 developed viremia within 3 wk; another chimpanzee given the same inoculum at a dose of 0.1 ID-50 has not developed viremia or seropositivity over a 6-mo follow-up.
No one has reported the isolation of HTLV-III/LAV from antihemophilic factor using macroculture isolation techniques despite compelling evidence that this material transmits AIDS (1) . It is likely that our assay does not measure the critical infectious dose of virus. No assay can discriminate one from zero infectious virus particles, and we are forced to rely on observed log reduction in the measurable range and extrapolation of thermal decay data to make inferences about efficacy of decontamination. Certainly, a procedure that reduces titer only 1 to 2 logs is insufficient to decontaminate Antihemophilic Factor because this reduction is obtained with lyophilization alone and lyophilized products transmit AIDS. However, the first-order kinetics of thermal decay and the long heating times, which are based on considerations for hepatitis virus inactivation (7) , indicate an expected reduction of 37 logs at 60'C in 20 h (and even greater for higher temperatures and times). This should provide a large, if not absolute, margin of safety. A preliminary clinical report supports the efficacy of heat treatment. Rouzioux et al. (8) followed a group of 18 hemophiliacs who were treated exclusively with heat-treated products. None seroconverted over a period of at least 6 mo compared with 5 seroconversions in 29 matched hemophilia controls treated with conventional product (8) . Thus, both in vitro and vivo data indicate that the use of heat-treated products will reduce (and hopefully terminate) AIDS transmission by antihemophilic factor.
